Johnson & Johnson R&D remained flat by 0.0% to $27.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 94.1%, from $460.25M to $27.25M.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ4 2025Feb 11, 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $483.00M | $1.84B | $109.00M |
| YoY Change | — | — | — | +281.2% | -94.1% |
Range$0.00 – $1.84B
Avg YoY Growth+93.5%
Median YoY Growth+93.5%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Innovative Medicine | $2.55B | $2.87B | $2.94B | $3.47B | $2.81B |
| MEDTECH | $677.00M | $647.00M | $728.00M | $786.00M | $714.00M |
| Total | $27.25M | $27.25M | $27.25M | $27.25M | — |
R&D at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's r&d?
- Johnson & Johnson (JNJ) reported r&d of $27.25M in Q4 2025.
- How has Johnson & Johnson's r&d changed year-over-year?
- Johnson & Johnson's r&d decreased by 94.1% year-over-year, from $460.25M to $27.25M.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.